- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 56-87-1] L-Lysine
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-N0469 |
| Brand: | MCE |
| CAS: | 56-87-1 |
Overview
| MDL | MFCD00064433 |
|---|---|
| Molecular Weight | 146.19 |
| Molecular Formula | C6H14N2O2 |
| SMILES | N[C@@H](CCCCN)C(O)=O |
3 Publications Citing Use of MCE
Summary
IC50 & Target
|
Human Endogenous Metabolite
|
Microbial Metabolite
|
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01155609 | University of Washington|National Cancer Institute (NCI) |
Mucositis|Oral Complications of Chemotherapy|Oral Complications of Radiation Therapy|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Nasopharynx|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Nasopharynx|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Basal Cell Carcinoma of the Lip|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Lymphoepithelioma of the Oropharynx|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity
|
September 2010 | Not Applicable |
| NCT00440804 | Farmacon |
Patent Ductus Arteriosus
|
December 2002 | Phase 3 |
| NCT05210504 | Vanderbilt University Medical Center |
Diabetes Mellitus, Type 2
|
March 9, 2022 | Phase 1 |
| NCT01220388 | University Hospital, Rouen |
Male|Healthy Volunteers
|
October 2010 | Not Applicable |
| NCT00996242 | Göteborg University|Stanley Medical Research Institute |
Schizophrenia
|
September 2007 | Not Applicable |
| NCT01579799 | University of Zurich |
Healthy
|
April 2012 | Not Applicable |
| NCT02756117 | Vanderbilt University|Vanderbilt University Medical Center |
Healthy|Pre-diabetic
|
May 2016 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 100 mg/mL ( 684.04 mM ; Need ultrasonic)
DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble or slightly soluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 6.8404 mL | 34.2021 mL | 68.4041 mL |
| 5 mM | 1.3681 mL | 6.8404 mL | 13.6808 mL |
| 10 mM | 0.6840 mL | 3.4202 mL | 6.8404 mL |
-
1.
Add each solvent one by one: PBS
Solubility: ≥ 100 mg/mL (684.04 mM); Clear solution
References
- [1] Al-Malki AL. Suppression of acute pancreatitis by L-lysine in mice. BMC Complement Altern Med. 2015 Jun 23;15:193.
- [2] Santos AMD, et al. Transitional metaplasia in intestinal epithelium of rats submitted to intestinal cystoplasty and treatment with L -lysine. Acta Cir Bras. 2017 Apr;32(4):297-306.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.